NCT03891953 2026-01-21Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.NovartisPhase 1 Active not recruiting98 enrolled
NCT06425926 2025-08-21Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsGeorgiamune IncPhase 1/2 Recruiting117 enrolled
NCT01351103 2025-06-13A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsNovartisPhase 1 Completed185 enrolled
NCT04261439 2025-05-06A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabNovartisPhase 1 Terminated60 enrolled
NCT03207867 2024-10-09A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaNovartisPhase 2 Terminated315 enrolled 73 charts
NCT03301896 2024-06-20Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1 Terminated45 enrolled
NCT02608268 2023-12-06Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Terminated252 enrolled 67 charts
NCT02607813 2022-12-21Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsNovartisPhase 1 Terminated142 enrolled
NCT02404441 2022-08-03Phase I/II Study of PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed319 enrolled 41 charts
NCT02807844 2021-08-11Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed141 enrolled 58 charts